Twist Licenses Bispecific Platform February 2026 Legal Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the ability to utilize the B- Body platform to expand service offerings and meet future demand for bisp ...

Core Insights - Compass Pathways plc has successfully achieved the primary endpoint in the ongoing Phase 3 COMP006 trial, which is the second of two Phase 3 trials evaluating COMP360 for treatment-resistant depression [1] Group 1 - The trial is assessing two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin [1] - The primary endpoint focused on the difference in change, indicating a significant milestone in the trial's progress [1]

Group 1 - Barclays raised its price target on CytomX Therapeutics, Inc. (CTMX) to $10 from $8 and maintained an Overweight rating [1] - Piper Sandler increased its price target to $10 from $6.50, maintaining an Overweight rating, following positive Phase I data on varsetatug maseatecan, which showed a 28% overall response rate and a 94% disease control rate [2] - Guggenheim initiated coverage with a Buy rating and a $10 price target, citing "extraordinary" antitumor activity from Varseta-M in heavily pre-treated patients [2] Group 2 - CytomX Therapeutics, Inc. develops conditionally activated biologics targeting the tumor microenvironment, including antibody-drug conjugates and T-cell engagers [3] - The company is expected to provide an update on approximately 100 metastatic colorectal cancer patients across various dose cohorts this quarter [2]

Core Insights - Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on gene therapies for rare diseases, with its lead product B-VEC in Phase III trials for dystrophic epidermolysis bullosa [1] - The consensus price target for Krystal Biotech's stock has increased from $269.25 a year ago to $327 last month, indicating growing analyst optimism [2][5] - The company projects 2025 revenues between $388 million and $389 million, supported by a strong cash reserve of $955 million, which is crucial for advancing its pipeline [3][5] - The clinical pipeline, including positive interim results for KB407, presents multibillion-dollar opportunities, with analysts expressing confidence in the company's growth potential [4][5]

Company Overview - Moderna, Inc. is a leading player in the biotech industry, recognized for its innovative mRNA technology and focus on developing vaccines and therapeutics, positioning it as a leader in the biomedical and genetics sector [1] Stock Performance - On February 16, 2026, UBS maintained a Neutral rating for Moderna, advising investors to hold the stock, with the stock priced at $42.23 and a revised price target adjusted from $34 to $36, indicating a cautious yet optimistic outlook [2] - Moderna's shares experienced a 5.3% increase on February 13, driven by investor interest in large-cap biotech companies, highlighting the positive sentiment surrounding the stock [3][6] - The stock has fluctuated between $41.23 and $44.80 on the day, with a 52-week high of $55.20 and a low of $22.28, reflecting its volatility in the market [5] Market Capitalization and Trading Volume - Moderna's market capitalization is approximately $16.5 billion, with a trading volume of 16,336,584 shares, indicating significant investor activity [4][6] Industry Sentiment - The biotech sector's improved outlook and institutional buying have contributed to positive sentiment surrounding Moderna, as investors are attracted to the company's blend of innovation and stability, recognizing its potential for sustained momentum beyond the pandemic-driven surge [4]

Core Viewpoint - Wave Life Sciences (NASDAQ:WVE) is identified as one of the biotechnology stocks with significant upside potential, with a consensus bullish sentiment among analysts and a projected price target indicating over 154% upside [1]. Group 1: Analyst Ratings and Price Targets - As of February 12, all 15 analysts covering Wave Life Sciences have assigned Buy ratings, with a median 1-year price target of $32.57 [1]. - William Maughan from Clear Street reiterated his Buy rating and raised the target price from $47 to $50, suggesting an upside of nearly 291% for investors [2]. Group 2: Company Developments and Pipeline - The transfer of rights to WVE-006 for alpha-1 antitrypsin deficiency from GlaxoSmithKline is viewed positively, although the greater significance lies in WVE-007 for the stock's valuation [3]. - Wave Life Sciences focuses on developing and commercializing RNA medicines, utilizing its PRISM technology platform for precision targeting of diseases [4]. - The company has a pipeline that includes WVE-006, WVE-007, and WVE-N531, indicating a diverse range of therapeutic programs [4].

Group 1 - Vaxcyte Incorporated (NASDAQ:PCVX) is identified as one of the 17 biotechnology stocks with more than 50% upside potential [1] - Cantor Fitzgerald maintains an Overweight rating on Vaxcyte, noting progress in its clinical pipeline, with the Phase 3 OPUS-1 trial topline readout expected in Q4 2026 and a BLA filing planned for the following year [1] - Needham analyst Joseph Stringer raised the price target for Vaxcyte from $90 to $110, indicating over 100% upside at current levels [3] Group 2 - Stringer's rating is supported by Vaxcyte's inclusion on Needham's Conviction List as a Top Pick for 2026, following positive Phase 2 data for VAX-31, which reduces risk ahead of the Phase 3 readout [4] - Vaxcyte is focused on developing next-generation vaccines for serious bacterial diseases, utilizing innovative synthetic methods and advanced chemistry to create complex, high-fidelity vaccines [5]

Group 1 - Beam Therapeutics (NASDAQ:BEAM) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a Buy rating and a price target of $80, indicating an upside of over 197% [1] - The company's recent agreement with the U.S. FDA to expedite the approval process for BEAM-302 in alpha-1 antitrypsin deficiency is a significant factor in the positive rating, allowing the use of AAT biomarker data over a 12-month horizon for future BLA [2] - Beam Therapeutics has a strong financial position, with nearly $1.25 billion in cash and marketable securities as of the end of 2025, sufficient to support operations until 2029 and fund the development of BEAM-302 and the anticipated launch of risto-cel [3] Group 2 - UBS analyst Michael Yee assigned a Neutral rating with a $28 price target on January 8, suggesting that more certainty for investors could benefit the biotech sector in 2026, with expectations of major catalysts and attractive pipelines driving returns [4] - Beam Therapeutics focuses on developing precision genetic medicines, engaging in gene therapies and genome editing research, and is a leader in CRISPR-based editing for advanced genetic medicine development [5]

Group 1 - Spyre Therapeutics (NASDAQ:SYRE) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a projected median 1-year price target of $57.86, indicating an upside of over 66% [1] - The company has received coverage from 7 analysts, all of whom have assigned Buy ratings, reflecting a strongly bullish consensus sentiment [1] - As of January 22, 2026, Spyre Therapeutics plans to prioritize six proof-of-concept (POC) readouts, with the SKYLINE ulcerative colitis trial completing SPY001 enrollment ahead of schedule, and the SKYWAY basket trial on track for fourth-quarter readouts in 2026 [2] Group 2 - Financially, Spyre Therapeutics reported $783 million in pro forma cash, cash equivalents, and marketable securities as of September 30, 2025, providing a runway through the second half of 2028 [2] - The company is a clinical-stage biotechnology firm focused on developing advanced antibody therapeutics for inflammatory bowel disease (IBD), including conditions such as ulcerative colitis and Crohn's disease [3] - Spyre's current pipeline includes multiple candidates: SPY001, SPY002, SPY003, and various combination therapies [3]

Company Overview - Arcellx Incorporated (NASDAQ:ACLX) is focused on developing advanced immunotherapies for cancer patients and other incurable conditions, utilizing proprietary D-Domain technology to create effective treatments targeting AML, multiple myeloma, and other malignancies [3]. Analyst Ratings - Rothschild & Co Redburn analyst Qize Ding downgraded Arcellx's rating from Buy to Neutral, reducing the price target from $113 to $82, indicating a revised upside potential of nearly 20% [1]. - Stifel analyst Stephen Willey reaffirmed a Buy rating with a price target of $127, suggesting an upside potential of 85% from the current level [2]. Clinical Data and Competitive Position - Willey's positive outlook followed the presentation of new laboratory study data at the TANDEM meeting, which indicated that anito-cel has a potentially leading safety profile with lower unintended immune activity and fewer off-target effects compared to rival CAR-T treatments [3]. - The data suggests that anito-cel may be positioned as a best-in-class therapy, differentiating it from cilta-cel (Carvykti) and ide-cel (Abecma) due to its reduced off-target interactions linked to severe delayed side effects [3]. Pipeline Development - The current pipeline includes the development of ACLX-001 and ACLX-002, targeting BCMA in relapsed/refractory multiple myeloma (rrMM) and CD123 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [3].